PSTV logoPSTV
Plus Therapeutics Inc

21,111
Loading...
Loading...
News
all
press releases
Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of +88.89% and -18.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of +47.44% and +116.92%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.43% and -0.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Plus (PSTV) Upgraded to Buy: Here's Why
Zacks·3mo ago
News Placeholder
The Cooper Companies (COO) Surpasses Q2 Earnings and Revenue Estimates
Zacks·4mo ago
News Placeholder
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates
Zacks·4mo ago
News Placeholder
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks·4mo ago
News Placeholder
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
Zacks·4mo ago
News Placeholder
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
Plus Therapeutics will secure $3 million in funding from the Department of Defense for pediatric brain cancer trial expansion. read more...
Benzinga·1y ago

Latest PSTV News

View

Advertisement. Remove ads.

Advertisement. Remove ads.